ATE180476T1 - 5h-indeno(1,2-b>pyrazin-2,3-dion-derivate antagonisten der ampa und nmda rezeptoren - Google Patents

5h-indeno(1,2-b>pyrazin-2,3-dion-derivate antagonisten der ampa und nmda rezeptoren

Info

Publication number: ATE180476T1
Authority: AT; Austria
Prior art keywords: pct; receptor; ampa; formula; indeno
Prior art date: 1994-03-28

Application number

AT95914405T

Other languages

English (en)

Inventor

Jean-Claude Aloup

Francois Audiau

Michel Barreau

Dominique Damour

Arielle Genevois-Borella

Patrick Jimonet

Serge Magnani

Yves Ribeill

Original Assignee

Rhone Poulenc Rorer Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-03-28

Filing date

1995-03-23

Publication date

1999-06-15

1995-03-23 Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa

1999-06-15 Application granted granted Critical

1999-06-15 Publication of ATE180476T1 publication Critical patent/ATE180476T1/de

Links

MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 title abstract 2
102000003678 AMPA Receptors Human genes 0.000 title abstract 2
108090000078 AMPA Receptors Proteins 0.000 title abstract 2
102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 title abstract 2
108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 title abstract 2
239000005557 antagonist Substances 0.000 title 1
ZYOYYQRWXITKFF-UHFFFAOYSA-N pyrazine-2,3-dione Chemical class O=C1N=CC=NC1=O ZYOYYQRWXITKFF-UHFFFAOYSA-N 0.000 title 1
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
239000002464 receptor antagonist Substances 0.000 abstract 2
229940044551 receptor antagonist Drugs 0.000 abstract 2
101100244083 Arabidopsis thaliana PKL gene Proteins 0.000 abstract 1
239000004471 Glycine Substances 0.000 abstract 1
239000002253 acid Substances 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
239000003446 ligand Substances 0.000 abstract 1
230000036963 noncompetitive effect Effects 0.000 abstract 1
125000004430 oxygen atom Chemical group O* 0.000 abstract 1
230000000144 pharmacologic effect Effects 0.000 abstract 1
102000005962 receptors Human genes 0.000 abstract 1
108020003175 receptors Proteins 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Child & Adolescent Psychology (AREA)
Anesthesiology (AREA)
Hematology (AREA)
Diabetes (AREA)
Toxicology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Obesity (AREA)
Nutrition Science (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Liquid Crystal Substances (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

AT95914405T 1994-03-28 1995-03-23 5h-indeno(1,2-b>pyrazin-2,3-dion-derivate antagonisten der ampa und nmda rezeptoren ATE180476T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR9403583A FR2717805B1 (fr)	1994-03-28	1994-03-28	Dérivés de 5H-indeno[1,2-b]pyrazine-2,3-dione, leur préparation et les médicaments les contenant .

Publications (1)

Publication Number	Publication Date
ATE180476T1 true ATE180476T1 (de)	1999-06-15

Family

ID=9461468

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT95914405T ATE180476T1 (de)	1994-03-28	1995-03-23	5h-indeno(1,2-b>pyrazin-2,3-dion-derivate antagonisten der ampa und nmda rezeptoren

Country Status (20)

Country	Link
US (1)	US5922716A (de)
EP (1)	EP0752988B1 (de)
JP (1)	JP3942631B2 (de)
KR (1)	KR970702262A (de)
AT (1)	ATE180476T1 (de)
AU (1)	AU692853B2 (de)
BR (1)	BR9507446A (de)
CA (1)	CA2184754A1 (de)
DE (1)	DE69509886T2 (de)
DK (1)	DK0752988T3 (de)
ES (1)	ES2134460T3 (de)
FI (1)	FI112219B (de)
FR (1)	FR2717805B1 (de)
GR (1)	GR3030274T3 (de)
HU (1)	HUT75307A (de)
IL (1)	IL113149A0 (de)
NO (1)	NO308075B1 (de)
PL (1)	PL316442A1 (de)
WO (1)	WO1995026342A1 (de)
ZA (1)	ZA952525B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK12293D0 (da) *	1993-02-02	1993-02-02	Novo Nordisk As	Heterocykliske forbindelser og deres fremstilling og anvendelse
FR2743363A1 (fr) *	1996-01-10	1997-07-11	Rhone Poulenc Rorer Sa	5h,10h-imidazo(1,2-a)indeno(1,2-e)pyrazine-a-ones substituees en position 2, leur preparation et les medicaments les contenant
US6083986A (en) *	1996-07-26	2000-07-04	Icagen, Inc.	Potassium channel inhibitors
US6333337B1 (en)	1998-01-27	2001-12-25	Icagen, Inc.	Potassium channel inhibitors
EP1240147A1 (de)	1999-12-21	2002-09-18	Icagen, Inc.	Kaliumkanalblocker
US6566380B2 (en)	2000-07-25	2003-05-20	Icagen, Inc.	Potassium channel inhibitors
US6620849B2 (en)	2000-07-26	2003-09-16	Icafen, Inc.	Potassium channel inhibitors
US6849634B2 (en)	2000-12-21	2005-02-01	Icagen	Potassium channel inhibitors
JP2005506292A (ja) *	2001-03-08	2005-03-03	エモリー　ユニバーシティ	ｐＨに依存するＮＭＤＡレセプターアンタゴニスト
US20040082543A1 (en) *	2002-10-29	2004-04-29	Pharmacia Corporation	Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain
US7732162B2 (en)	2003-05-05	2010-06-08	Probiodrug Ag	Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
US8278345B2 (en)	2006-11-09	2012-10-02	Probiodrug Ag	Inhibitors of glutaminyl cyclase
ATE554085T1 (de)	2006-11-30	2012-05-15	Probiodrug Ag	Neue inhibitoren von glutaminylcyclase
JP5930573B2 (ja)	2007-03-01	2016-06-15	プロビオドルグエージー	グルタミニルシクラーゼ阻害剤の新規使用
WO2008128985A1 (en)	2007-04-18	2008-10-30	Probiodrug Ag	Thiourea derivatives as glutaminyl cyclase inhibitors
KR20100045983A (ko)	2007-06-29	2010-05-04	에모리 유니버시티	신경보호를 위한 ｎｍｄａ 수용체 길항물질
PL2475428T3 (pl)	2009-09-11	2015-12-31	Probiodrug Ag	Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
ES2586231T3 (es)	2010-03-03	2016-10-13	Probiodrug Ag	Inhibidores de glutaminil ciclasa
MX2012010470A (es)	2010-03-10	2012-10-09	Probiodrug Ag	Inhibidores heterociclicos d ciclasa de glutaminilo (qc, ec .3 2. 5).
US8541596B2 (en)	2010-04-21	2013-09-24	Probiodrug Ag	Inhibitors
CN101906051B (zh) *	2010-07-13	2013-01-23	成都理工大学	手性氨基茚酮的合成方法
EP2686313B1 (de)	2011-03-16	2016-02-03	Probiodrug AG	Benzimidazolderivate als glutaminylcyclase-hemmer
PL3461819T3 (pl)	2017-09-29	2020-11-30	Probiodrug Ag	Inhibitory cyklazy glutaminylowej

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4507300A (en) *	1980-05-09	1985-03-26	Usv Pharmaceutical Corporation	Pyridotriazolopyrazine-diones for treating allergy
US4668678A (en) *	1980-05-09	1987-05-26	Usv Pharmaceutical Corporation	Triazoloquinoxalin-1,4-diones
US4400382A (en) *	1980-05-09	1983-08-23	Usv Pharmaceutical Corporation	Thiazoloquinoxalin-1,4-diones for treating allergy
US4354027A (en) *	1980-05-19	1982-10-12	Usv Pharmaceutical Corporation	Triazoloquinoxalin-4-ones
US5196421A (en) *	1991-06-05	1993-03-23	Eli Lilly And Company	Excitatory amino acid receptor antagonists in methods for the use thereof
US5153196A (en) *	1991-06-05	1992-10-06	Eli Lilly And Company	Excitatory amino acid receptor antagonists and methods for the use thereof
DK162491D0 (da) *	1991-09-20	1991-09-20	Novo Nordisk As	Heterocycliske forbindelser, deres fremstilling og farmaceutiske praeparater indeholdende forbindelserne
DK0647137T3 (da) *	1992-06-22	2008-12-08	State Of Oregon Through Oregon	Glycinreceptorantagonister og anvendelse deraf
FR2696466B1 (fr) *	1992-10-02	1994-11-25	Rhone Poulenc Rorer Sa	Dérivés de 5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one, leur préparation et les médicaments les contenant.
DK12293D0 (da) *	1993-02-02	1993-02-02	Novo Nordisk As	Heterocykliske forbindelser og deres fremstilling og anvendelse
FR2707645B1 (fr) *	1993-07-16	1995-08-11	Rhone Poulenc Rorer Sa	Dérivés d'imidazo[1,2-a]pirazine-4-one, leur préparation et les médicaments les contenant.
FR2707643B1 (fr) *	1993-07-16	1995-08-11	Rhone Poulenc Rorer Sa	Dérivés d'imidazo[1,2-a]pyrazine-4-one, leur préparation et les médicaments les contenant.

1994
- 1994-03-28 FR FR9403583A patent/FR2717805B1/fr not_active Expired - Fee Related
1995
- 1995-03-02 CA CA002184754A patent/CA2184754A1/fr not_active Abandoned
- 1995-03-23 BR BR9507446A patent/BR9507446A/pt not_active Application Discontinuation
- 1995-03-23 US US08/714,164 patent/US5922716A/en not_active Expired - Fee Related
- 1995-03-23 AU AU21414/95A patent/AU692853B2/en not_active Ceased
- 1995-03-23 PL PL95316442A patent/PL316442A1/xx unknown
- 1995-03-23 ES ES95914405T patent/ES2134460T3/es not_active Expired - Lifetime
- 1995-03-23 WO PCT/FR1995/000359 patent/WO1995026342A1/fr not_active Ceased
- 1995-03-23 EP EP95914405A patent/EP0752988B1/de not_active Expired - Lifetime
- 1995-03-23 HU HU9602658A patent/HUT75307A/hu unknown
- 1995-03-23 DK DK95914405T patent/DK0752988T3/da active
- 1995-03-23 JP JP52499695A patent/JP3942631B2/ja not_active Expired - Fee Related
- 1995-03-23 DE DE69509886T patent/DE69509886T2/de not_active Expired - Fee Related
- 1995-03-23 AT AT95914405T patent/ATE180476T1/de not_active IP Right Cessation
- 1995-03-27 IL IL11314995A patent/IL113149A0/xx unknown
- 1995-03-28 ZA ZA952525A patent/ZA952525B/xx unknown
1996
- 1996-09-25 KR KR1019960705453A patent/KR970702262A/ko not_active Withdrawn
- 1996-09-26 NO NO964059A patent/NO308075B1/no not_active IP Right Cessation
- 1996-09-27 FI FI963881A patent/FI112219B/fi active
1999
- 1999-05-27 GR GR990400320T patent/GR3030274T3/el unknown

Also Published As

Publication number	Publication date
HU9602658D0 (en)	1996-11-28
CA2184754A1 (fr)	1995-10-05
DK0752988T3 (da)	1999-11-08
JPH09510728A (ja)	1997-10-28
FI963881L (fi)	1996-09-27
HUT75307A (en)	1997-05-28
PL316442A1 (en)	1997-01-20
ES2134460T3 (es)	1999-10-01
FR2717805A1 (fr)	1995-09-29
NO964059L (no)	1996-09-26
DE69509886D1 (de)	1999-07-01
EP0752988B1 (de)	1999-05-26
FI963881A0 (fi)	1996-09-27
ZA952525B (en)	1996-01-15
NO308075B1 (no)	2000-07-17
AU692853B2 (en)	1998-06-18
AU2141495A (en)	1995-10-17
FI112219B (fi)	2003-11-14
KR970702262A (ko)	1997-05-13
GR3030274T3 (en)	1999-08-31
JP3942631B2 (ja)	2007-07-11
IL113149A0 (en)	1995-06-29
EP0752988A1 (de)	1997-01-15
US5922716A (en)	1999-07-13
NO964059D0 (no)	1996-09-26
WO1995026342A1 (fr)	1995-10-05
BR9507446A (pt)	1997-08-12
DE69509886T2 (de)	1999-09-30
FR2717805B1 (fr)	1996-05-10

Legal Events

Date	Code	Title
2000-01-15	UEP	Publication of translation of european patent specification
2005-03-15	EEFA	Change of the company name
2009-12-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE69509886D1 (de)	1999-07-01	5H-INDENO[1,2-b]PYRAZIN-2,3-DION-DERIVATE ANTAGONISTEN DER AMPA UND NMDA REZEPTOREN
FR2717812B1 (fr)	1996-05-10	Indeno[1,2-e]pyrazine-4-ones, leur préparation et les médicaments les contenant.
AU681688B2 (en)	1997-09-04	Imidazo(1,2-a)pyrazine-4-one, preparation thereof and drugs containing same
NZ515304A (en)	2004-01-30	Bradykinin receptor antagonists
FR2726275B1 (fr)	1996-12-06	Spiro heterocycle-imidazo(1,2-a)indeno(1,2-e)pyrazine)-4'- ones, leur preparation et les medicaments les contenants
FR2717813B1 (fr)	1996-05-10	Dérivés d'imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one, leur préparation et les médicaments les contenant .
DK0756602T3 (da)	2000-01-31	CCK- eller gastrin-modulerende 5-heterocyclo-1,5-benzodiazepiner
TR199900096T2 (xx)	1999-03-22	Bradykinin B2 antagonistleri olarak elveri�li N-benzensulfonil-L-prolin t�revleri.
MX9707528A (es)	1997-11-29	Derivados de 5h,10h-imidazo[1,2-a]indeno[1,2-e]pirazin-4-ona, su preparacion y los medicamentos que los contienen.
BG105178A (bg)	2001-12-29	Нови 2,3,3а,4,9,9а-хексахидро-8-хидрокси-1н-бенз/f/индоли, метод за получаването им и приложението им като лекарствени средства